Oral uracil-tegafur: An alternative to intravenous 5-fluorouracil?

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 9, 2001, Pages 1495-1505

  Jones, R ^a   Twelves, C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer; Cytotoxic; Oral fluoropyrimidines; UFT; Uracil tegafur

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; CAPECITABINE; CISPLATIN; DOXORUBICIN; EMITEFUR; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NUCLEOSIDE ANALOG; OXALIPLATIN; PACLITAXEL; PRODRUG; TEGAFUR; UFT; URACIL; VINDESINE;

ABDOMINAL PAIN; ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG PREFERENCE; DRUG USE; EUROPE; FATIGUE; GRANULOCYTOPENIA; HUMAN; JAPAN; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; NEUTROPENIA; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SIDE EFFECT; STOMACH CANCER; STOMATITIS; UNITED STATES; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; TEGAFUR; URACIL;

EID: 0034839451     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.9.1495     Document Type: Article

References (77)

1. Oncoprotein networks
2. Tumour suppressor genes: Evolving definitions in the genomic age
3. 5-fluoropyrimidines
4. S phase of the cell cycle
5. Kinetics and thermodynamics of the interaction of 5-fluoro-2-deoxyuridylate and thymidylate synthase
6. Variations in patterns of DNA degradation induced in human colorectal cancer cells by 5-fluorodeoxyuridine; implications for mechanisms of resistance and cytotoxicity
7. Fluororinated pyrimidines: A new class of tumour inhibitory compounds
8. An overview of the current status and future directions of clinical trials of 5-fuorouracil and folinic acid
9. For the Advanced Colorectal Metanalysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
10. The inhibitory effects of 5-fluorouracil on the metabolism of pre-ribosomal and ribosomal RNA in L-1210 cells in vitro
11. 5-Fluorouracil substitution alters pre-mRNA splicing in vitro
12. 5-fluororacil incorporation in DNA of human breast carcinoma cells
13. 5-fluororacil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity
14. Relationship between fluorouracil systemic exposure and tumour response and patient survival
15. Efficacy of intravenous infusion of fluorouracil compared to bolus administration in advanced colorectal cancer
16. Impact of protracted venous infusion with or without interferon alpha on tumour response, survival, and quality of life in advanced colorectal cancer
17. Oral chemotherapy: Rationale and future directions
18. A study of quality of life in cancer patients receiving palliative chemotherapy
19. Patient preferences for oral versus intravenous palliative chemotherapy
20. A randomised crossover trial comparing UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer
21. Population study of dihydropyrimidine dehydrogenase in cancer patients
22. The oral fluoropyrimidines in cancer chemotherapy
23. Analogues of pyrimidine nucleosides
24. Clinical experience with UFT in Japan
25. Effect of uracil and its derivatives on antitumour activity of 5-fluorouracil and I-(2-tetrahydrofuryl)-5 fluorouracil
26. Clinical application of biochemical modulation in cancer chemotherapy: Biochemical modulation of 5FU
27. Concentration of 5-FU-level in the tissue and blood of patients with breast cancer by preoperative administration of UFT
28. Concentration of 5-FU-level in the tissue and blood of patients with head and neck malignant tumours by preoperative administration of UFT
29. Studies on combination therapy with 1-(tetrahydro-2-furanyl)-5-fluorouracil plus uracil
30. Studies on combination therapy with 1-(tetrahydro-2-furanyl)-5-fluorouracil plus uracil
31. Subacute toxicity of UFT, a new anti-cancer agent orally administered in rats
32. Subacute toxicity of UFT, a new anti-cancer agent orally administered in dogs
33. Comparative steady state pharmacokinetics of oral UFT versus protracted infusion 5-fluorouracil
34. Pharmacokinetics of Ftorafur after iv. and oral administration
35. Effect of co-administration of uracil on the toxicity of ftorafur
36. Phase 1 trials of Uracil-Tegafur (UFT) using 5 and 28 day administration schedules: Demonstration of schedule dependent toxicities
37. Phase I and clinical pharmacological studies of oral UFT alone and with leucoverin (LV)
38. Phase 1 and pharmacokinetic study of oral UFT, a combination of the 5-fourouracil prodrug tegafur and uracil
39. Phase I clinical trials and pharmacokinetics of uracil-ftorafur combination (UFT) plus leucovorin (LV) in patients with advanced colorectal cancer
40. Phase I trial of uracil-tegafur (UFT) plus oral leucoverin: 14-day schedule
41. Phase 1 trial of Uracil-Tegafur (UFT) plus oral leucovorin: 28-day schedule
42. A Phase I pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer
43. Preliminary results of phase I clinical trial; UFT modulated by folinic acid (PO) in treatment of advanced colorectal cancer
44. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer
45. Phase II trial of Uracil and Tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma
46. UFT plus leucovorin (LV) in advanced colorectal cancer. A Phase II trial
47. Oral uracil/tegafur (UFT) plus leukovorin in patients with metastatic colorectal cancer
48. Efficacy of oral Tegafur modulation by uracil and leucovorin in advanced colorectal cancer; a Phase II study
49. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience
50. Tegafur-uracil (UFT) plus folinic acid in advanced rectal-cancer
51. Report on nationwide pooled data and cohort investigation in UFT Phase II study Cancer Chemother
52. Phase II trial of UFT in advanced colorectal and gastric cancer
53. Is dose normalisation to weight or body surface area useful in adults
54. Multicenter phase III study of 5-Fluoruracil (5FU) or UFT in combination with leucovorin in patients with metastatic colorectal cancer
55. Randomized comparative study of UFT plus leucovorin versus parenteral 5-Fluorouracil (5FU) plus leucovorin in patients with metastatic colorectal cancer
56. UFT-leucovorin as adjuvant treatment for Dukes' B2-C colon cancer
57. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: A prospective randomised clinical trial
58. A Phase III randomised study of oral UFT (tegafur plus uracil) as maintenance therapy in adjuvant treatment of surgically resected colorectal cancer
59. Phase II trial of uracil-tegafur (UFT), leucovorin (LV) and Mitomycin C in advanced colorectal cancer
60. Irinotecan combined with fluorouracil compared to fluorouracil alone as first line treatment for metastatic colorectal cancer: A multicentered randomised trial
61. Phase I/II study of oral UFT, leucoverin and irinotecan in patients with advanced colorectal cancer
62. Phase I clinical study of Irinotecan (CPT-11) in combination with UFT/folic acid (FA) in patients with advanced colorectal cancer (CRC)
63. Leucovorin and fluorouracil with or without treatment in oxaliplatin as first line treatment in advanced colorectal cancer
64. A Phase I study of oral uracil/tegafur (UFT) plus leucovorin (LV) combined with oxaliplatin in patients with metastatic colorectal cancer (CRC)
65. Randomised trial comparing epirubucin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced oesophagogastric cancer
66. Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): A Phase I-II study in patients with advanced upper gastrointestinal tract cancer
67. A phase II study of epirubicin, cisplatin, UFT, and leucovorin in advanced gastric carcinomas
68. A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: A Mid Atlantic Oncology Program Study
69. Phase II study of UFT mixture in patients with advanced non-small cell lung cancer
70. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced non-small-cell lung carcinoma
71. A Phase II trial of oral UFT and cisplatin in patients with advanced non-small-cell lung carcinoma
72. Adjuvant chemotherapy after complete resection in non-small cell lung cancer
73. A Phase II study of oral uracil and ftorafur (UFT) plus leucovorin (ORZEL) in advanced local-regional or metastatic squamous cell carcinoma of the head and neck carcinoma
74. Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic cancer
75. Phase I-II trial of increasing dose, continuous UFT plus leucovorin with fixed dose three weekly doxorubicin (D) and paclitaxel (P) in locally advanced breast cancer (LABC)
76. A phase III trial of XELODA (capecitabine) in previously untreated advanced/metastatic colorectal cancer
77. A phase III trial of XELODA (capecitabine) in previously untreated advanced/metastatic colorectal cancer